Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma

Cancer Science

Volumn 106, Issue 2, 2015, Pages 186-193

  Tateishi, Ukihide ^a   Tatsumi, Mitsuaki ^b   Terauchi, Takashi ^c   Ando, Kiyoshi ^d   Niitsu, Nozomi ^e   Kim, Won Seog ^f   Suh, Cheolwon ^g   Ogura, Michinori ^h   Tobinai, Kensei ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKAI UNIVERSITY HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^f Samsung Medical Center   (South Korea)

^g Asan Medical Center   (South Korea)

^h NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Diffuse large B cell lymphoma; Lymphoma; Metabolic tumor burden; Positron emission tomography computed tomography; F 18 fluorodeoxyglucose

Indexed keywords

BENDAMUSTINE; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GLYCOLYSIS; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR BURDEN; MULTICENTER STUDY; ONCOLOGICAL PARAMETERS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG EFFECTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 84927680568     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12588     Document Type: Article

References (32)

1. Ogura M, Ando K, Taniwaki M et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Cancer Sci 2011; 102: 1687-92.
2. Ohmachi K, Niitsu N, Uchida T et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013; 31: 2103-9.
3. Itti E, Lin C, Dupuis J, Paone G et al. Prognostic value of interim F-18 FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 527-33.
4. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 20: 3059-3068.
5. Zinzani PL, Gandolfi L, Broccoli A et al. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011; 117: 1010-8.
6. Yang D-H, Min J-J, Song H-C et al. Prognostic significance of interim (18)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011; 47: 1312-8.
7. Terasawa T, Lau J, Bardet S et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-14.
8. Casasnovas RO, Meignan M, Berriolo-Riedinger A et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011; 118: 37-43.
9. Kim TM, Paeng JC, Chun IK et al. Total lesion glycolysis in positron emission tomography is a bettwerpredictor of outcome than the International prognostic index for patients with diffuse large B cell lymphoma. Cancer 2012; 119: 1195-202.
10. Berkowitz A, Basu S, Srinivas S et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 2009; 29: 521-6.
11. Rossi M, Korkola P, Pertovaara H et al. PET imaging in a longitudinal non-Hodgkin's lymphomastudy: association with tumor volume. Acta Radiol 2011; 52: 995-1002.
12. Song MK, Chung JS, Shin HJ et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci 2012; 103: 477-82.
13. Song MK, Chung JS, Shin HJ et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91: 697-703.
14. Tseng D, Rachakonda LP, Su Z et al. Interim-treatment quantitative PET parameters predict prgression and death among patients with Hodgin's disease. Radiat Oncol 2012; 7: 5.
15. Esfahani SA, Heidari P, Halpern EF et al. Baseline total lesion glycolysis measured with 18F-FDG PET/CT as a predictor of progression-free survival in diffuse large B cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging 2013; 3: 272-81.
16. Huang B, Chan T, Kwong DLW et al. Nasopharyngeal carcinoma: investigation of intratumoral heterogeneity with FDG PET/CT. AJR Am J Roentogenol 2012; 199: 169-74.
17. Vriens D, Disselhorst JA, Oyen WJ et al. Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET. Int J Radiat Oncol Biol Phys 2012; 82: e725-31.
18. van Velden FHP, Cheebsumon P, Yaqub M et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoral FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 2011; 38: 1636-47.
19. Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med 2014; 55: 37-42.
20. Hanaoka K, Hosono M, Usami K et al. Fluorodeoxyglucose uptake in the bone marrow after granulocyte-stimulating factor administration in patients with non-Hodgkin's lymphoma. Nucl Med Commun 2011; 32: 678-83.
21. Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-66.
22. Boellaard R, O'Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
23. Scheuermann JS, Saffer JR, Karp JS et al. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med 2009; 50: 1187-93.
24. Fukukita H, Senda M, Terauchi T et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010; 24: 325-34.
25. Wahl RL, Jacene H, Kasamon Y et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S-50S.
26. Larson SM, Erdi Y, Akhurst T et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Pos Imag 1999; 2: 159-71.
27. Gallamini A, Hutching M, Rigacci L et al. Early interm 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
28. Itti E, Meignan M, Berriolo-Riedinger A et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging 2013; 40: 1312-20.
29. Coleman RE, Delbeke D, Guiberteau MJ et al. Concurrent PET/CT with an integrated imagingsystem: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005; 46: 1225-39.
30. Horning SJ, Juweid ME, Schoder H et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010; 115: 775-7.
31. Watabe T, Tatsumi M, Watabe H et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med 2012; 26: 222-7.
32. Biggi A, Gallamini A, Chauvie S et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013; 54: 683-90.